Amicus Therapeutics, Inc.
FOLD
Classificação em ações
#3706
Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery,... Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified by in vitro assay data. The company's pipeline also includes several investigational therapies: AT-GAA, an innovative treatment strategy for Pompe disease; various enzyme replacement therapies aimed at Pompe diseases; and AT-GTX-502, an AAV serotype gene therapy for CLN3. The latter is currently undergoing Phase 1/2 clinical studies to evaluate the safety and efficacy of a single intrathecal administration in patients with CLN3. Additionally, Amicus is exploring therapeutic approaches related to CDKL5, a gene on the X-chromosome that encodes a protein essential for regulating proper brain development. Amicus maintains strategic collaborations and licensing arrangements with prominent entities such as Nationwide Children's Hospital, the University of Pennsylvania, and GlaxoSmithKline. The company was founded in 2002 and is based in Philadelphia, Pennsylvania.
Preço da ação
$14.49
Última sincronização: 2026-04-27
Valor de mercado
$4.55B
Variação (1 dia)
0.00%
Variação (1 ano)
71.07%
País
US
Negociar Amicus Therapeutics, Inc. (FOLD)
Categoria
Healthcare
Receita da Amicus Therapeutics, Inc. (FOLD)
Receita em Dec 2025 TTM: $634.21M
De acordo com os últimos relatórios financeiros da Amicus Therapeutics, Inc., a receita atual da empresa (TTM) é $634.21M. Em 2023, a empresa obteve uma receita de $399.36M um aumento em relação a a receita do ano 2022, que foi de $329.23M. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Amicus Therapeutics, Inc. de 2003 a 2026
Receita no final de cada ano
| Ano | Receita | Alterar |
|---|---|---|
| 2026 (TTM) | $634.21M | 20.05% |
| 2024 | $528.30M | 32.29% |
| 2023 | $399.36M | 21.30% |
| 2022 | $329.23M | 7.76% |
| 2021 | $305.51M | 17.11% |
| 2020 | $260.89M | 43.16% |
| 2019 | $182.24M | 99.72% |
| 2018 | $91.25M | 147.08% |
| 2017 | $36.93M | 644.86% |
| 2016 | $4.96M | 0.00% |
| 2015 | 0.00 | -100.00% |
| 2014 | $1.22M | 237.19% |
| 2013 | $363.00K | -98.03% |
| 2012 | $18.41M | -14.10% |
| 2011 | $21.43M | 2,224.73% |
| 2010 | $922.00K | -98.57% |
| 2009 | $64.36M | 330.00% |
| 2008 | $14.97M | 738.96% |
| 2007 | $1.78M | 0.00% |
| 2006 | 0.00 | 0.00% |
| 2005 | 0.00 | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | 0.00% |
Receita de empresas similares ou concorrentes
| Empresa | Receita | Diferença de Receita | País |
|---|---|---|---|
| $12.62B | 1,890.56% |
US
|
|
| $2.23B | 251.30% |
US
|
|
| $15.74B | 2,382.51% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 849.42% |
NL
|
